Entasis Therapeutics Holdings Inc. (ETTX)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Entasis Therapeutics Holdings Inc. (ETTX) with AI Score 44/100 (Weak). Entasis Therapeutics Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing antibacterial products to combat multidrug-resistant infections. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Entasis Therapeutics Holdings Inc. (ETTX) Healthcare & Pipeline Overview
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, pioneers antibacterial solutions targeting multidrug-resistant pathogens. Their lead candidate, SUL-DUR, addresses critical unmet needs in treating severe infections like pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii, positioning them in a high-demand segment of the biotechnology sector.
Investment Thesis
Entasis Therapeutics, now a subsidiary of Innoviva, presents a focused investment opportunity within the antibiotic development space. The primary value driver is the potential success of SUL-DUR in treating carbapenem-resistant Acinetobacter baumannii infections. Positive Phase III clinical trial results and subsequent regulatory approval could significantly increase its value. Zoliflodacin, targeting uncomplicated gonorrhea, represents another potential revenue stream. However, the company faces risks associated with clinical trial outcomes, regulatory hurdles, and competition from other antibacterial therapies. The company's beta of 1.33 indicates higher volatility than the market. Success hinges on navigating these challenges and effectively commercializing its pipeline.
Based on FMP financials and quantitative analysis
Key Highlights
- Lead product candidate SUL-DUR is in Phase III clinical trials targeting carbapenem-resistant Acinetobacter baumannii infections.
- Zoliflodacin, an orally administered molecule, is also in Phase III clinical trials for the treatment of uncomplicated gonorrhea.
- Collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR.
- Collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of zoliflodacin.
- Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.
Competitors & Peers
Strengths
- Promising lead product candidate (SUL-DUR) in Phase III trials.
- Focus on addressing a critical unmet need in treating multidrug-resistant infections.
- Strategic collaborations with Zai Lab and GARDP.
- Pipeline of novel antibacterial compounds.
Weaknesses
- Clinical-stage company with no currently marketed products.
- Reliance on successful clinical trial outcomes and regulatory approvals.
- High cash burn rate associated with drug development.
- Dependence on partnerships for development and commercialization.
Catalysts
- Upcoming: Release of Phase III clinical trial results for SUL-DUR.
- Upcoming: Potential FDA submission and approval for SUL-DUR.
- Upcoming: Advancement of ETX0282CPDP and ETX0462 through clinical trials.
Risks
- Potential: Failure to achieve positive clinical trial results for SUL-DUR or other drug candidates.
- Potential: Regulatory setbacks or delays in approval processes.
- Ongoing: Competition from established pharmaceutical companies and other biotechnology firms.
- Ongoing: High cash burn rate associated with drug development.
Growth Opportunities
- SUL-DUR Commercialization: Successful completion of Phase III trials and subsequent FDA approval for SUL-DUR could unlock a significant market opportunity in treating carbapenem-resistant Acinetobacter baumannii infections. The increasing prevalence of these infections in hospital settings creates a substantial unmet need. Market size estimates for targeted antibiotics exceed $1 billion annually. The timeline for potential commercialization is dependent on trial results and regulatory review, potentially within the next 2-3 years.
- Zoliflodacin Market Expansion: Zoliflodacin, targeting uncomplicated gonorrhea, represents another growth avenue. The rising incidence of antibiotic-resistant gonorrhea strains necessitates new treatment options. The global market for gonorrhea treatment is estimated at several hundred million dollars annually. Successful Phase III trial outcomes and regulatory approval could position Zoliflodacin as a key player in this market, potentially within the next 2 years.
- Expansion of Pipeline: Advancing ETX0282CPDP and ETX0462 through clinical trials represents a longer-term growth opportunity. These drug candidates target urinary tract infections and multidrug-resistant gram-negative infections, respectively. Success in these programs could broaden Entasis's product portfolio and address additional unmet medical needs. The timeline for these programs extends beyond 3-5 years.
- Strategic Partnerships: Leveraging existing collaborations with Zai Lab and the Global Antibiotic Research and Development Partnership, Entasis can further expand its reach and accelerate the development and commercialization of its products. Exploring new partnerships with pharmaceutical companies or research institutions could provide access to additional resources and expertise. The impact of strategic partnerships is ongoing and can influence multiple aspects of the business.
- Geographic Expansion: Initially focused on the United States, Entasis can explore opportunities to expand its geographic reach to other markets, particularly in Europe and Asia, where the prevalence of multidrug-resistant infections is also increasing. This expansion could involve establishing partnerships with local distributors or pursuing direct commercialization efforts. The timeline for geographic expansion is dependent on regulatory approvals and market access considerations in each region.
Opportunities
- Growing market for novel antibiotics to combat multidrug-resistant infections.
- Potential for accelerated regulatory pathways for drugs targeting serious infections.
- Expansion of pipeline through internal research and development or acquisitions.
- Geographic expansion to markets outside the United States.
Threats
- Failure to achieve positive clinical trial results.
- Regulatory setbacks or delays in approval processes.
- Competition from established pharmaceutical companies and other biotechnology firms.
- Changes in reimbursement policies or market access restrictions.
Competitive Advantages
- Proprietary drug candidates with patent protection.
- Clinical trial data demonstrating efficacy against multidrug-resistant pathogens.
- Strategic collaborations with established pharmaceutical companies.
- Expertise in antibiotic development and regulatory affairs.
About ETTX
Founded in 2015 and headquartered in Waltham, Massachusetts, Entasis Therapeutics Holdings Inc. is dedicated to the discovery, development, and commercialization of novel antibacterial products. The company's mission is to address the growing global threat of multidrug-resistant infections. Their lead product candidate, sulbactam-durlobactam (SUL-DUR), is a novel intravenous antibiotic currently in Phase III clinical trials for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. This pathogen poses a significant challenge in healthcare settings due to its resistance to many commonly used antibiotics. Beyond SUL-DUR, Entasis is also developing Zoliflodacin, an orally administered molecule in Phase III clinical trials for uncomplicated gonorrhea. Additionally, ETX0282CPDP, an oral drug, is in Phase I clinical trials targeting urinary tract infections. The company's pipeline also includes ETX0462, a drug candidate from their NBP platform, currently in the pre-clinical stage, aimed at treating multidrug-resistant gram-negative infections. Entasis has established strategic collaborations to advance its pipeline, including a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR, and a collaboration agreement with the Global Antibiotic Research and Development Partnership for the development and commercialization of zoliflodacin. In 2022, Entasis Therapeutics was acquired and now operates as a subsidiary of Innoviva, Inc.
What They Do
- Discovers and develops antibacterial products.
- Focuses on treating serious infections caused by multidrug-resistant pathogens.
- Develops intravenous and orally administered antibiotics.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Collaborates with other companies and organizations to advance its pipeline.
- Seeks regulatory approval for its products from agencies like the FDA.
Business Model
- Develops and patents novel antibacterial compounds.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval to market and sell its products.
- Partners with other companies for development and commercialization.
Industry Context
The biotechnology industry is characterized by high-risk, high-reward ventures, particularly in the antibiotic development sector. The increasing prevalence of multidrug-resistant organisms is driving demand for new antibacterial therapies. However, the development and regulatory approval processes are lengthy and expensive. Entasis Therapeutics operates in a competitive landscape with established pharmaceutical companies and other biotechnology firms also focused on developing novel antibiotics. Success depends on demonstrating clinical efficacy, navigating regulatory pathways, and securing market access.
Key Customers
- Hospitals and healthcare systems treating patients with serious infections.
- Patients suffering from infections caused by multidrug-resistant pathogens.
- Government agencies and public health organizations focused on combating antibiotic resistance.
Financials
Chart & Info
Entasis Therapeutics Holdings Inc. (ETTX) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Monday
· Mar 16, 2020
-
Stocks Which Set New 52-Week Low Friday, October 26th
· Oct 29, 2018
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ETTX.
Price Targets
Wall Street price target analysis for ETTX.
MoonshotScore
What does this score mean?
The MoonshotScore rates ETTX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Manoussos Perros
CEO
Manoussos Perros serves as the CEO of Entasis Therapeutics Holdings Inc. His leadership is pivotal in guiding the company's strategic direction and overseeing the development of its antibacterial pipeline. His responsibilities include managing the company's 51 employees and driving the advancement of key clinical programs. Additional details regarding his background and experience are not available.
Track Record: Information on Manoussos Perros's specific achievements and milestones at Entasis Therapeutics is not available. His leadership is focused on advancing the company's clinical programs and securing regulatory approvals.
Entasis Therapeutics Holdings Inc. Stock: Key Questions Answered
What does Entasis Therapeutics Holdings Inc. do?
Entasis Therapeutics Holdings Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antibacterial products to treat serious infections caused by multidrug-resistant pathogens. Their lead product candidate, SUL-DUR, targets carbapenem-resistant Acinetobacter baumannii infections. The company also has other drug candidates in various stages of clinical development, targeting infections such as uncomplicated gonorrhea and urinary tract infections. Entasis collaborates with other companies and organizations to advance its pipeline and address the growing global threat of antibiotic resistance.
What are the main risks for ETTX?
The primary risks for Entasis Therapeutics revolve around the inherent uncertainties of drug development. These include the potential for clinical trial failures, regulatory setbacks, and competition from other companies developing antibacterial therapies. Additionally, the company faces financial risks associated with its high cash burn rate and dependence on partnerships for funding and commercialization. The emergence of new antibiotic resistance mechanisms could also impact the long-term viability of its products.
What is Entasis Therapeutics Holdings Inc.'s drug pipeline status?
Entasis Therapeutics Holdings Inc.'s pipeline includes SUL-DUR, currently in Phase III clinical trials for treating pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. Zoliflodacin, an orally administered molecule, is also in Phase III clinical trials for uncomplicated gonorrhea. ETX0282CPDP, targeting urinary tract infections, is in Phase I clinical trials, and ETX0462 is in the pre-clinical stage, aimed at treating multidrug-resistant gram-negative infections. The company's pipeline reflects its focus on addressing critical unmet needs in the treatment of serious bacterial infections.
What are the key factors to evaluate for ETTX?
Entasis Therapeutics Holdings Inc. (ETTX) currently holds an AI score of 44/100, indicating low score. Key strength: Promising lead product candidate (SUL-DUR) in Phase III trials.. Primary risk to monitor: Potential: Failure to achieve positive clinical trial results for SUL-DUR or other drug candidates.. This is not financial advice.
How frequently does ETTX data refresh on this page?
ETTX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ETTX's recent stock price performance?
Recent price movement in Entasis Therapeutics Holdings Inc. (ETTX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Promising lead product candidate (SUL-DUR) in Phase III trials.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ETTX overvalued or undervalued right now?
Determining whether Entasis Therapeutics Holdings Inc. (ETTX) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ETTX?
Before investing in Entasis Therapeutics Holdings Inc. (ETTX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be subject to change.
- The company is a clinical-stage biopharmaceutical company, and its future success depends on the successful development and commercialization of its drug candidates.